Autopsy report · NCT01639131
Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma
Cause of deathNo reason given
Life of this trial
- Registered 2 months before it started.
- Ran for about 6 years 6 months before it stopped.
- 6 participants enrolled.
- Results were posted on the registry 3 years 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Sponsor type
- University, hospital or other
- Conditions
- Metastatic Colorectal Adenocarcinoma
- Interventions
- Gemcitabine; Docetaxel; Filgrastim or Pegfilgrastim
- Participants
- 6
- Sites
- 3
- Countries
- Netherlands, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.